[HTML][HTML] Current perspectives in cancer immunotherapy
Different immunotherapeutic approaches have proved to be of significant clinical value to
many patients with different types of advanced cancer. However, we need more precise …
many patients with different types of advanced cancer. However, we need more precise …
[HTML][HTML] The anti-VEGF (R) drug discovery legacy: improving attrition rates by breaking the vicious cycle of angiogenesis in cancer
Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …
[HTML][HTML] Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?
Although the ever-increasing number of cancer patients pose substantial challenges
worldwide, finding a treatment with the highest response rate and the lowest number of side …
worldwide, finding a treatment with the highest response rate and the lowest number of side …
[HTML][HTML] Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro
Non-small cell lung cancer (NSCLC) is reported to have a high incidence rate and is one of
the most prevalent types of cancer contributing towards 85% of all incidences of lung cancer …
the most prevalent types of cancer contributing towards 85% of all incidences of lung cancer …
[HTML][HTML] Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling
Simple Summary A clinical decision and study design investigating the level and extent of
angiogenesis modulation aimed at vascular normalization without rendering tissues hypoxic …
angiogenesis modulation aimed at vascular normalization without rendering tissues hypoxic …
[HTML][HTML] Pancreatic cancer signaling pathways, genetic alterations, and tumor microenvironment: The barriers affecting the method of treatment
Genetic alterations, especially the K-Ras mutation, carry the heaviest burden in the
progression of pancreatic precursor lesions into pancreatic ductal adenocarcinoma (PDAC) …
progression of pancreatic precursor lesions into pancreatic ductal adenocarcinoma (PDAC) …
[HTML][HTML] The role of V-domain Ig suppressor of T cell activation (VISTA) in cancer therapy: lessons learned and the road ahead
Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory
ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of …
ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of …
[HTML][HTML] Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
J Mo, X Hu, L Gu, B Chen, PA Khadaroo… - World journal of surgical …, 2020 - Springer
Background Immune checkpoint inhibitors, which are a milestone in anti-cancer therapy,
have been applied in the treatment of multiple malignancies. Real-world data have …
have been applied in the treatment of multiple malignancies. Real-world data have …
[HTML][HTML] New insights into diffuse large B-cell lymphoma pathobiology
AG Solimando, T Annese, R Tamma, G Ingravallo… - Cancers, 2020 - mdpi.com
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL),
accounting for about 40% of all cases of NHL. Analysis of the tumor microenvironment is an …
accounting for about 40% of all cases of NHL. Analysis of the tumor microenvironment is an …
[HTML][HTML] The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma
C Xu, S Sui, Y Shang, Z Yu, J Han, G Zhang… - Journal of advanced …, 2020 - Elsevier
The details of the immunological microenvironment and its clinical implications for
pancreatic cancer are still unclear. In this study, we obtained data from public databases …
pancreatic cancer are still unclear. In this study, we obtained data from public databases …